Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 12, 2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026
– Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year
Read more at globenewswire.com
